# 5 An autopsy was not performed. The physician assessed the

**Page range:** 274–274

```text
5. An autopsy was not performed. The physician assessed the
causality of pneumonia as not related to pralsetinib."
2889538
54
Female
UNITED
STATES
OF
AMERICA
Clinical
Study
Healthcare
professional
COVID-19
Grade 5
5
(1) PRALSETINIB (S)

(2) PREDNISONE (T)

(3) SALBUTAMOL (T)
Drug interrupted
Negative
N/A
Fatal
"AER 2889538 (PT: COVID-19):

This clinical study case concerned a 54-year-old female (patient
number: 2608015) from the USA who developed COVID-19
infection, 5 days after starting therapy with pralsetinib for lung
neoplasm malignant and non-small cell lung cancer. The
patient’s medical history, concurrent conditions, concomitant
medications and past drugs were not reported. On Cycle 1 Day
1, the patient received study drug pralsetinib at a dose of 300 mg
(frequency unspecified) and received till Study Day 421. On
Study Day 426, the patient developed first episode of Grade 3
COVID-19 and was hospitalized due to exacerbated dyspnea
related to COVID-19. The treatment regimen included a six-day
course of prednisone and albuterol. On Study Day 444, the
patient recovered with sequelae from the first episode of COVID-
```